STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization orphan drug tax credit, and orphan drug provisions of HR 1, Tax Cuts and Jobs Act Issues related to access to rare and orphan disease therapeutics under the enactment of ACA; Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES DERDERIAN | — |
| SARAH HAMLETT | Legislative Director, Rep. Thelma Drake; Legislative Assistant, Rep. Schrock |
| VALERIE HENRY | — |
| JOSEPH RACHINSKY | — |
| EMILY SHETTY | — |
| ERIN STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.